Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
Summary
- Conditions
- Amyotrophic Lateral Sclerosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Prospective, double blind, placebo control, randomized 2:1 studyMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: The subjects, care givers, investigator, and coordinator will be blinded. The pharmacist, who will be responsible for the drug supply, will be unblinded. The investigational drug and the placebo will have identical pill shape and color. They will be supplied in identical boxes.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03427086
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Achraf Makki, MD American University of Beirut Medical Center Principal Investigator: Johnny Salameh, MD American University of Beirut Medical Center
Get Well Soon